Crohn's disease

R&D

The rise and market race of anti-IL23p19 therapies in IBD: H...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two decades.

News

INTERCEPT trial team at a meeting in Vienna

Takeda backs biomarker trial for Crohn's prevention

The INTERCEPT trial aims to validate biomarkers that could identify people at risk of Crohn's and see if treatment can prevent symptoms developing.

News

Lilly nets a second FDA okay for Omvoh, in Crohn's disease

Eli Lilly picks up a second FDA approval for IL-23 inhibitor Omvoh in Crohn's disease, but will it kickstart sales growth?

News

Teva, Sanofi score well with anti-TL1A drug in IBD test

Phase 2b results with Sanofi and Teva's duvakitug are exciting and warrant a swift move to phase 3 in inflammatory bowel disease, say the companies.

News

Lilly swoops on Morphic to claim IBD drug candidate

Eli Lilly has bolstered its inflammatory bowel disease (IBD) pipeline with a $3.2 billion bid to acquire Morphic and its mid-stage oral integrin therapy MORF-057.

News

AbbVie licenses FutureGen IBD drug in $1.7bn deal

The high value attached by pharma companies to inflammation and immunology (I&I) programmes is on display once again, as AbbVie agrees a deal worth up to $1.7 billion for an inflammator

The rise and market race of anti-IL23p19 therapies in IBD: H...

Takeda backs biomarker trial for Crohn's prevention

Lilly nets a second FDA okay for Omvoh, in Crohn's disease

Teva, Sanofi score well with anti-TL1A drug in IBD test

Lilly swoops on Morphic to claim IBD drug candidate

AbbVie licenses FutureGen IBD drug in $1.7bn deal

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Crohn's disease

Editor's Picks